Free Trial

Precision BioSciences (DTIL) Competitors

Precision BioSciences logo
$4.34 -0.01 (-0.12%)
As of 12:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DTIL vs. EPRX, ENGN, TLSA, CTMX, OGI, GNFT, FDMT, IPHA, VTYX, and DERM

Should you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Eupraxia Pharmaceuticals (EPRX), enGene (ENGN), Tiziana Life Sciences (TLSA), CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry.

Precision BioSciences vs. Its Competitors

Precision BioSciences (NASDAQ:DTIL) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Precision BioSciences currently has a consensus price target of $47.00, indicating a potential upside of 984.20%. Eupraxia Pharmaceuticals has a consensus price target of $11.00, indicating a potential upside of 102.21%. Given Precision BioSciences' higher possible upside, research analysts clearly believe Precision BioSciences is more favorable than Eupraxia Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precision BioSciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Eupraxia Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

38.0% of Precision BioSciences shares are owned by institutional investors. 4.0% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Precision BioSciences has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision BioSciences$68.70M0.70$7.17M-$2.01-2.16
Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-7.16

In the previous week, Precision BioSciences and Precision BioSciences both had 2 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.14 beat Precision BioSciences' score of 0.12 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Precision BioSciences Neutral
Eupraxia Pharmaceuticals Positive

Precision BioSciences has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Precision BioSciences' net margin of -42.99%. Precision BioSciences' return on equity of -69.26% beat Eupraxia Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Precision BioSciences-42.99% -69.26% -29.30%
Eupraxia Pharmaceuticals N/A -367.73%-112.23%

Summary

Precision BioSciences beats Eupraxia Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Precision BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DTIL vs. The Competition

MetricPrecision BioSciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$48.08M$2.88B$5.48B$8.96B
Dividend YieldN/A2.44%5.22%4.00%
P/E Ratio-2.1621.1127.4720.11
Price / Sales0.70291.21429.10116.97
Price / CashN/A41.7026.2128.59
Price / Book0.637.447.965.59
Net Income$7.17M-$55.14M$3.17B$248.65M
7 Day Performance3.21%4.09%4.61%7.54%
1 Month Performance-21.04%0.79%2.78%8.47%
1 Year Performance-52.88%4.95%35.48%21.79%

Precision BioSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DTIL
Precision BioSciences
4.5046 of 5 stars
$4.34
-0.1%
$47.00
+984.2%
-52.4%$48.08M$68.70M-2.16200
EPRX
Eupraxia Pharmaceuticals
2.4579 of 5 stars
$5.76
+8.7%
$11.00
+91.0%
+117.3%$190.57MN/A-7.5829Gap Up
High Trading Volume
ENGN
enGene
2.7791 of 5 stars
$3.64
-0.5%
$23.29
+539.7%
-57.6%$187.04MN/A-2.2131
TLSA
Tiziana Life Sciences
0.6703 of 5 stars
$1.58
-1.3%
N/A+85.5%$186.96MN/A0.008Positive News
CTMX
CytomX Therapeutics
3.8444 of 5 stars
$2.27
+0.9%
$5.33
+134.9%
+93.0%$181.40M$138.10M4.73170
OGI
Organigram Global
0.5318 of 5 stars
$1.35
flat
N/A-10.4%$180.82M$117.47M13.50860
GNFT
GENFIT
1.9781 of 5 stars
$3.73
+3.2%
$13.00
+249.0%
-8.2%$180.49M$67.00M0.00120Positive News
Gap Up
FDMT
4D Molecular Therapeutics
2.2772 of 5 stars
$3.71
-3.4%
$29.56
+696.6%
-80.6%$177.89M$40K-1.17120
IPHA
Innate Pharma
2.5278 of 5 stars
$1.82
-1.9%
$11.00
+506.1%
-8.5%$170.53M$21.77M0.00220
VTYX
Ventyx Biosciences
2.3768 of 5 stars
$2.14
-8.5%
$10.00
+367.3%
-3.5%$166.52MN/A-1.2230
DERM
Journey Medical
1.918 of 5 stars
$7.18
+0.6%
$9.50
+32.3%
+36.3%$166.33M$56.13M-18.4190Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:DTIL) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners